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Abstract
Background: PCR-based serotyping of Streptococcus pneumoniae has been proposed as a simpler approach than
conventional methods, but has not been applied to strains in Asia where serotypes are diverse and different from other part
of the world. Furthermore, PCR has not been used to determine serotype distribution in culture-negative meningitis cases.
Methodology: Thirty six serotype-specific primers, 7 newly designed and 29 previously published, were arranged in 7
multiplex PCR sets, each in new hierarchies designed for overall serotype distribution in Bangladesh, and specifically for
meningitis and non-meningitis isolates. Culture-negative CSF specimens were then tested directly for serotype-specific
sequences using the meningitis-specific set of primers. PCR-based serotyping of 367 strains of 56 known serotypes showed
100% concordance with quellung reaction test. The first 7 multiplex reactions revealed the serotype of 40% of all, and 31%
and 48% non-meningitis and meningitis isolates, respectively. By redesigning the multiplex scheme specifically for non-
meningitis or meningitis, the quellung reaction of 43% and 48% of respective isolates could be identified. Direct
examination of 127 culture-negative CSF specimens, using the meningitis-specific set of primers, yielded serotype for 51
additional cases.
Conclusions: This PCR approach, could improve ascertainment of pneumococcal serotype distributions, especially for
meningitis in settings with high prior use of antibiotics.
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Introduction
Streptococcus pneumoniae is the predominant cause of bacterial
pneumonia, a leading cause of meningitis, and results in more than
800,000 deaths yearly among children under–5 worldwide [1].
Pneumococcal meningitis in developing countries is often recognized
late, resulting in high mortality and a substantial burden of long-term
disability among survivors. The prospects for prevention of pneumo-
coccal disease and averting deaths are now substantial through mass
vaccination using conjugate pneumococcal vaccines [2–6].
In many countries, particularly resource poor countries,
however, implementing an effective vaccine programme is
challenging both in terms of cost and for determining the true
burden of diseases, because many pneumococcal meningitis cases
are culture negative [7,8]. Thus, it is not possible to know which
serotype caused the disease in most cases, and in turn which
capsular antigens should be incorporated into the vaccine. Of the
90 different possible serotypes, disease is caused by a restricted set
that can differ markedly between countries. The currently licensed
vaccine, a 7-valent pneumococcal conjugate vaccine (PCV7), is
based on the predominant serotypes causing invasive disease in
North America, and, while it affords protection to .80% of
invasive pneumococcal cases in these settings, it is predicted to
protect against only 60% and 40% of cases in Africa and Asia,
respectively [9]. Moreover, recent observations in Bangladesh
[10–12] and surrounding countries [13,14] suggest that this 7-
valent formulation may only protect against 25% to 40% of
invasive pneumococcal disease among under 5 year-old children.
Although coverage of pneumococcal serotypes with the PCV7
and other upcoming vaccines is estimated to be lowest in Asia, the
calculations are based on a small number of isolates. This paucity
of data arises from the following factors: i) CSF samples are not
routinely collected in Asia, even if the clinical suspicion is very
high, ii) few laboratories successfully culture pneumococcus in
cases of pneumococcal disease and iii) even fewer laboratories have
the resources to serotype the isolates.
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serotype distribution is that most cases, including meningitis,
remain culture negative due to widespread use of antibiotics prior
to presenting to the hospital. This limits the survey of capsular
serotype distribution of pneumococcal invasive disease and also
potentially biases towards antibiotic resistant strains/serotypes. A
molecular approach that identifies a pneumococcal etiology and its
serotype among both culture positive and culture negative cases
would offer greater precision in pneumococcal serotype surveil-
lance and in vaccine design.
Presently, serotyping of pneumococci is dependent on isolation
of the organism followed by serological determination by quellung
reaction (capsular swelling) [15]. The high cost of antisera, the
requirements for technical skills and the complexity in interpre-
tation of results are major hindrances of this procedure, thus
further limiting its use in resource poor environments. To
overcome these barriers and simplify capsular typing of pneumo-
cocci, different initial molecular approaches were attempted;
however, they were of limited value and could not be easily used
for comprehensive surveillance [16–21].
The availability of sequences of the cps loci for all 90 known
pneumococcal serotypes (http://www.sanger.ac.uk/Projects/
S_pneumoniae/CPS/) has facilitated the design of primers for a
sequential multiplex polymerase chain reaction (PCR) for capsular
serotyping of pneumococci [22,23], though the primer selection
and their arrangement for multiplexing was optimized based on
the capsular serotype distribution found in the USA. Despite this
geographic limitation in its design, this scheme has been used
successfully in field studies on isolates from Brazil and South Africa
[24,25]. There is an urgent need to redesign and optimize the test
for the divergent serotypes encountered in Bangladesh and
neighboring countries [10–14].
In this study we aimed to a) modify the design of the sequential
multiplex PCR method of Pai et al. [23] to optimize the scheme for
the capsular serotype distribution likely to occur in Bangladesh, b)
validate the scheme in Bangladeshi strains isolated from meningitis
and non-meningitis cases, c) apply the scheme to detect capsular
serotype directly from cerebrospinal fluid (CSF) specimens of culture
positive and culture negative cases of pneumococcal meningitis and
d) to compare the cost and laboriousness of two serotyping methods.
Methods
Setting
The study was carried out at Department of Microbiology, Dhaka
Shishu Hospital (DSH), the largest pediatric hospital in Bangladesh
that provides both primary and tertiary care. DSH has 450 beds of
which 50% provide free care, including investigations, food and
essential first-line medicines/antibiotics. Nonpaying beds are
reserved for those who cannot afford to pay for their care. Lumbar
puncture is routinely done for all suspected cases of meningitis, and
CSF specimens are analyzed in the Department of Microbiology.
The department is conducting laboratory surveillance for
bacterial etiology of meningitis since 1993 [10,11,26–28]. In
addition, since 2004, the surveillance for invasive pneumococcal
diseases is extended to a network of 7 hospitals through a
PneumoADIP sponsored study [29] (Figure S1).
Serotyping of strains by Quellung reaction
Pneumococcal strains were serotyped by the capsular swelling
procedure (quellung reaction) with anti-pneumococcal omni, pool,
type or group, and factor sera (Statens Serum Institut, Copenha-
gen, Denmark) as described previously [26,30].
Primer design and validation
Five new primers not included in the study of Pai et al. [23] were
designed based on serotype distribution of pneumococcus isolates
from pneumonia and meningitis cases enrolled at 7 hospitals of
Bangladesh during January 04 to December 06 [29], and 2 other
primers (serogroup 12 and 15) were redesigned to yield product
sizes appropriate for the reformulated multiplex PCR scheme. All
the primers targeted the wzy/wzx region of the capsulation locus
[22,23], using sequences downloaded from http://www.ncbi.nlm.
nih.gov/Genbank for each of the capsular serotypes/groups; for
accession numbers, see Table 1.
Newly designed primers were tested for their specificity and
cross reactivity against the quellung reaction as gold standard. A
full panel of available 56 different serotypes was subjected to
amplification. For any discrepant PCR results, we re-confirmed
serotype by quellung reaction and re-adjusted the PCR scheme to
achieve optimal conditions to resolve these discrepancies.
Table 1. New oligo-nucleotide primers designed in this study.
Serotype Accession no. Sequence Gene location at cps loci Primer position Product size
2 CR931633. F GTCATTGTTACGATTAGTTTCGATAGTTGAGG wchI 11162–12319 11221–11601 381
R AATTCAATTCCTAAGTCCTCTTCCATAAACTC
45 CR931718 F GTTTAATGGCTGATGAAGTTATTATTGTTG wcxS 10753–11673 10832–11069 238
R TTTACCATCAGTGAAATTTTATCTTTGTTC
24 A/F CR931686. F TCTCAACCAAGATACAGATTTTGATTTTACTC wcxI 12794–13717 12868–13553 686
R TATAAACCTTTAGTAAACACTCTGCTTGATCG
23B CR931684 F TTGTTAGTGGTATTAAATTGGGGACTACTAGG wzx 12455–13843 12938–13145 216
R ATACCTATCTGAAGTGTTATTAACCCACCAAC
29 CR931694 F ATTATCTCGGATCAAACAATTCTTTTGTAAAC wzy 6231–7412 6970–7228 259
R AACGCTAACATTAAAACTAGAACGAGTAAACC
15B/C CR931664. F AGGAATCAGATATTATCATTACTCATGGTG wchK-wzy 6612–8277 6799–7294 496
R TCATGACCCATAGAACTATATAAAAAGACG
12 A/F CR931658 F ACTCTTCCAAATTCTTATGCTTTTATTGATTC wzy 11091–12302 11136–11778 656
R ATGAATGAGAAAAGGAACTTAAAATTCATAGC
doi:10.1371/journal.pone.0003576.t001
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Three hundred and seventy six invasive pneumococcal isolates
of 56 different serotypes (1, 2, 3, 4, 5, 6A, 6B, 7A, 7C, 7F, 8, 9N,
9V, 10A, 10F, 11A, 11B, 12A, 12B, 12F, 13, 14, 15A, 15B, 15C,
15F, 16F, 17F, 18A, 18B, 18C, 18F, 19A, 19F, 20, 21, 22A, 22F,
23A, 23B, 23F, 24A, 24B, 24F, 25F, 29, 31, 33B, 33F, 34, 35A,
35B, 35F, 38, 45, 48) were used to validate the new primers. Of
these, 257 strains were collected from Bangladesh; 141 were
isolated at DSH and 116 were obtained from the 6 hospitals
participating in the extended surveillance. Others were received
from Oxford University, UK (N= 92), Centers for Disease
Control and Prevention, USA (N=15) and Novartis laboratory,
Italy (N=12), kindly provided by Drs. Derrick Crook, Bernard
Beall and Michele Barocchi respectively.
Primer sets for sequential multiplex testing
The primers were incorporated into 7 sets for sequential testing
based on the descending prevalence of pneumococcal isolates
occurring from January ’04 to December ’07. Depending on the
ranking of capsular types among pneumonia/sepsis and meningitis
cases, the panel of 7 sets of primers was further modified to
specifically accommodate the different serotype distributions in
these two different disease syndromes [11,26,29].
Cases for CSF specimens
During 2004–2007, 11,114 CSF specimens were received at the
DepartmentofMicrobiology, DSH,for analysis. Of these, 1,828 had
$10 cell count/mm
3, and considered as the cases of meningitis.
Pneumococcal meningitis cases (N=358) were defined based on
isolation of the organism or detection of pneumococcal antigen,
either by latex agglutination test (LAT; Wellcogen Bacterial Antigen
Kit;RemelEuropeLtd,Kent, UK) or immunochromatographic test
(ICT) (Binax NOW Streptococcus pneumoniae test, Binax Inc., Portland,
ME, USA) from CSF (Figure 1).
PCR method
Isolates. PCR reactions for pneumococcus were performed as
described by Pai et al. [23] with minor modifications. In brief,
multiplex PCR was done in 25 ml reaction volume containing
12.5 ml Qiagene Hot Start multiplex PCR master mix with 2.5 mlo f
equimolar (0.2 mM) primer mix, 2 ml of boiled bacterial suspension
and 8 ml of distilled water. PCR tubeswere placed ina thermalcycler
(DNA Engine, BioRad, Hercules, California, USA) programmed for
initial denaturation at 95uC for 15 min followed by 30 cycles of
amplificationat 94uCfor45seconds,annealingat56uCfo r1mi n30
seconds, and extension at 72uC for 1min 40 seconds with final
extension at 72uC for 10 min. PCR products were electrophoresed
in a 2% agarose gel at 90 volts for 150 min, stained with ethidium
bromide and visualized by transillumination (Ultra-Violet Products
ltd, Upland, California, USA).
CSF specimens. Detection of serotype-specific sequences of
pneumococcus in CSF specimens was initially standardized and
validated by using the culture positive specimens, keeping the
respective isolate as control. Based on initial difficulties in
amplifying the serotype sequences in culture positive CSF
specimens, possibly due to inhibitory substances [31], the
specimens were treated with Proteinase K (Sigma-Eldrich,
Steinheim, Germany) and precipitated by ethanol to remove
inhibitors [32]. The PCR reaction mixture for CSF was equivalent
to the mixture for strains, except that 10 ml of CSF was added
instead of bacterial lysate and H2O. For all PCR reactions, primer
for universal pneumococcal genome (cps) was incorporated as the
control. While running the culture-negative CSF specimens,
isolates of known serotypes were included as a built-in positive
control for respective multiplex primer sets.
Figure 1. Study profile of CSF specimens with results.
doi:10.1371/journal.pone.0003576.g001
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th
pneumococcal isolate was cross checked by an independent and
blinded person. In case of PCR, a set of 5 isolates of known serotype,
were tested by PCR in a blinded way. This was done twice a year by
using two different set of randomly selected isolates.
Reagent costs and work load. Cost of typing was calculated
based on the number of isolates (n=219) typed in the last 3 years as
the antisera generally expires after 3 years from the time of arrival at
the laboratory. For quellung reaction, the cost was calculated for one
vialof eachantiseraspecificallyneeded fortyping of ourisolates.The
cost of PCR-based typing included the price of consumables,
disposables and quality assurance required for typing the same
number of strains. Personnel and capital equipment costs were not
considered in the calculation for either of the methods.
Work load was determined on the basis of reactions needed
specifically for serotyping of pneumococcal isolates of this study.
For capsular swelling method, cumulative reactions needed for
pools, groups and types were considered. On the other hand, for




P-values were calculated using Statcalc calculator of Epi Info 6.02.
Ethics
Strains and specimens used in this study were obtained from
patients enrolled in different studies. All of them were approved by
the Ethical Review Committee (ERC) of Bangladesh Institute of
Child Health, DSH. The studies were also approved by the ERC
of the collaborative organizations; Johns Hopkins University, USA
and International Centre for Diarrhoeal Disease Research,
Bangladesh (ICDDR,B).
Results
The 5 newly designed primers showed 100% specificity when
tested using individual isolates of each of 56 different serotypes; there
were no discrepant results. The sequential multiplex PCR scheme
(Figures 2 and 3), as expected, identified the capsular serotype of
isolates in decreasing order of frequency. The first of 7 multiplex
reactions yielded the capsular serotype of 40% of strains and, by the
end of reaction 4, it reached to 85%. The capsular serotype of 94%
of isolates could be determined when using all 7 multiplex reactions
(Figure 2A). The initial multiplex design identified the serotype of
31% (N=39/125) and 48% (N=64/132) of pneumonia/sepsis and
meningitis isolates, respectively (p=0.007). By redesigning the
multiplex scheme specifically for pneumonia/sepsis or meningitis,
the capsular serotype of 43% and 48% of isolates could be identified
Figure 2. Multiplex PCR schemes and their coverage for Pneumococcal serotypes of Bangladesh
doi:10.1371/journal.pone.0003576.g002
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st reaction, and 86% and 88% of isolates by the 4
th
reaction, respectively (Figure 2B, 2C).
During January 2004 to December 2007, there were 358 (20%;
358/1,828) cases of pneumococcal meningitis enrolled at DSH;
however, an isolate was grown from only 136 (38%; 136/358)
cases. For the other 222 (62%; 222/358) culture-negative cases,
the etiology was determined either by LAT (41%; 92/222) or
Binax (59%; 130/222). Of these 222 cases, 127 (48 and 79
positives based on LAT and ICT testing, respectively) had
sufficient remaining CSF for performing sequential multiplex
PCR. PCR yielded the capsular serotype for an additional 51
(40%; 51/127) cases, although the cps was positive for all 127 cases.
The yield of positive capsular serotype identity by PCR was higher
(p,0.001) from the LAT positive cases (77%, 37/48) than from
LAT-negative ICT-positive cases (18%, 14/79) (Figure 1). The
proportional distribution of PCR-detected serotypes from culture
negative cases was similar to the serotype distribution of isolates
identified from CSF cultures, except for serotypes 1 and 24, which
ranked 2nd and 23rd, respectively, among the cultured isolates,
compared to 6th and 3rd, respectively, among the serotypes
detected from culture negative cases by PCR (Figure 4A, 4B).
Vaccine coverage for serotypes of culture positive meningitis cases
by the existing PCV-7 and the upcoming 10 and 13-valent
vaccines were 18%, 33% and 42%, respectively. On the other
hand, coverage for PCR detected serotypes from culture negative
cases was 18%, 33% and 33%, in that order. Coverage of the 3
vaccine formulations for all meningitis-causing serotypes (detected
by any method) was 18%, 37% and 40%, respectively.
The calculated cost for serotype determination of 219 strains,
collected in 3 years time were US$22,640 for quellung reaction
and US$9,688 for PCR method.
Conventional serotyping by quellung reactions required 2,466
reactions (1,186 for pools, 880 for groups and 400 for types). In
contrast, PCR based typing needed 688 PCR reactions.
Discussion
New formulations of pneumococcal conjugate vaccines with
higher valency (i.e. 10 and 13 serotypes), aiming for higher coverage
and wider use, will soon become available. Recently, Advance
Market Commitment (AMC) (http://www.vaccineamc.org/) an-
nounced the hope of customizing a pneumococcal vaccine with
optimal coverage for all regions, based on region and/or country-
specific serotype data, and introducing it promptly in developing
countries, including South Asia. To achieve this, the World Health
Organization and GAVI’s PneumoADIP are working through a
Global Serotype Project (GSP) to estimate the burden of serotype-
specific pneumococcal disease,by region, sub-region orcountry,and
finally to devise an appropriate target product profile.
Recent use of PCR-based typing has expanded our knowledge
of serotype distributions; however, the prevalence of serotypes by
disease syndrome and locale is still lacking from many regions. To
address that, we designed new primers and rearranged the
sequential multiplex PCR reaction scheme according to the
predicted distribution of pneumococcal serotypes in Bangladesh.
The 1
st reaction of the multiplex PCR scheme (Figure 2)
reported here could detect the serotype of up to 40% of invasive
pneumococcal cases. This contrasts to the 1
st reaction of the
schemes designed for use to identify serotypes of major importance
in the USA, Africa and Latin America [23–25], which would
detect only 9%, 18% and 19% of the same Bangladeshi isolates,
respectively, indicating the wide differences in distribution of
serotypes by geography. Further, Bangladeshi serotypes are also
divergent as indicated by lower (66%) cumulative yield from the 1
st
two multiplex reactions specifically designed for the respective
countries, compared to the serotypes of Africa (82%) and Latin
America (80%) [24,25]. The serotype coverage of US strains by
multiplex PCR reactions are not shown as the distribution in the
USA has been dramatically changed following introduction of the
7-valent conjugate vaccine.
The 1
st multiplex reaction following initial customization of the
Bangladesh-specific battery of multiplex PCR reactions detected a
lower proportion (31%) of pneumonia/sepsis isolates compared to
meningitis cases (48%; p=0.007), mainly due to the excess of
serotype 2 among the meningitis cases. Rearrangement of the
multiplex reaction schemes accordingly improved the detection of
pneumonia/sepsis isolates from 31% to 43% in first reaction. This
shows the relative simplicity of this approach to optimizing the
multiplex reaction for specific needs, whether geographical or for
specific disease syndromes.
In recent years, sensitive diagnostic tests like LAT and Binax
have substantially improved measurement of the burden of
pneumococcal meningitis [7], specifically in areas where pre-
admission use of antibiotics is common such as Asia [8]. However,
these tests do not provide capsular serotype information,
Figure 3. Amplified serotype (1, 2, 14 & 18) genome from culture negative CSF specimens by 1st reaction of multiplex PCR scheme.
Lane 1–10 & 14–17: Culture negative latex Positive CSF, Lane 11–13: Culture negative ICT Positive CSF, Lane 18: Positive Control Containing amplified
cps gene and genome of 4 known isolates of reaction 1, L 19: Reagent control–reagents devoid template, L 20: 100bp ladder.
doi:10.1371/journal.pone.0003576.g003
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358 cases of pneumococcal meningitis among which only 38%
(136/358) yielded an isolate; the rest (62%) were identified either
by LAT (41%; 92/222) or ICT (59%; 130/222). The sequential
multiplex PCR scheme was shown to readily identify the capsular
serotype not only of isolates but also directly from CSF samples of
culture-negative cases, which was not possible with the Quellung
method. The PCR scheme revealed the capsular serotype of an
additional 51 cases among 127 available culture-negative speci-
mens, which is equivalent to 38% (51/136) of the culture-positive
cases accumulated in the past 48 months. Isolation of this number
of strains and identification of their serotype distribution by
conventional methods would take about 18 additional months of
surveillance and processing of 4,168 specimens, representing a
substantial savings of time and money.
Cost of conventional Quellung-based capsular serotyping is 2.4
times more than PCR-based typing, considering the consumables
only. In respect of work load, quellung needs about 4 times more
number of reactions than PCR. It needs to be mentioned that
typing by quellung reaction is more laborious and requires more
person time, in comparison to PCR-based typing, even for the
same number of reactions [24,25]. Further, PCR-based serotyping
can incorporate built-in controls for quality assurance (QA) of the
whole procedure (Figure 3). Nonetheless, capsular serotype data
on 171 pneumococcal meningitis cases could not be revealed.
Among them, 95 had insufficient specimen to test by PCR, and in
another 76 cases sequential multiplex PCR failed to identify the
capsular serotype despite samples being positive for capsular
elements (i.e. cps). Failure of the reaction in these cases (N=76)
could be due to one or more of the following factors: i) insufficient
PCR template concentration, ii) presence of residual inhibitory
factors, and/or iii) disease caused by uncommon serotypes for
which primers are not yet designed and thus omitted from the
sequential multiplex PCR (e.g. 10F, 19B, 23A, etc.). It is important
to address all these issues to improve the performance and yield of
PCR-based capsular serotyping of culture-negative specimens.
Lack of sufficient CSF is a common problem, particularly when
derived from clinical services; this could be addressed, however, by
development of an algorithm of tests relevant to routine patient
care. For example, the specimen volume required could be
minimized by centralizing all biochemical and microbiological
testing in one place, for example the microbiology laboratory, and
by testing specimens first with ICT rather than immediately
applying both LAT and ICT tests.
In addition to increased cost effectiveness, simplicity and built-in
QA of the PCR-based method, multiplex PCR also has the
potential to reveal a different distribution of serotypes circulating
in the population compared to culture-positive cases. In this study,
serotype 24 ranked 23
rd in culture-positive cases but ranked 2
nd
among the culture-negative cases. On the other hand, serotype 1
ranked 2
nd in culture-positive cases in contrast to its 6
th position
among culture-negative cases (Figure 4A, 4B). The difference in
serotype distribution of culture-negative cases marginally impacted
the overall serotype distribution, possibly because the number of
cases was small in comparison to the total number of isolates (51
Vs 136). However, the effect may have been conspicuous if
serotype information was revealed from all the culture-negative
cases. This could have major impact on formulating the valency of
region-specific conjugate vaccines.
The findings reported here are proof-of-principal for value of
sequential multiplex PCR capsular serotyping for determination of
regional serotype distribution and specifically among cases of
pneumococcal meningitis. There is ample scope for improving the
yield of the method, by making it more sensitive and adding more
Figure 4. Distribution of capsular types among A) Isolates and B) Culture negative meningitis cases.
doi:10.1371/journal.pone.0003576.g004
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6A/6B, 12A/12B and 18A/18B/18C. The approach has an
important limitation as it will solely increase serotype information
from meningitis cases. This shortcoming is critical to keep in mind,
as pneumonia serotypes are somewhat different and it causes more
deaths than meningitis. Nonetheless, to minimize this, we are
extending our work to serotyping of cases with culture-negative
and antigen-positive blood culture bottles [33,34] and pleural
fluids. Despite the limitations, the application of the approach
described here will offer precise surveillance data on capsular
serotype in many more settings by eliminating the complexity of
pneumococcal serotyping and the impact of prior antibiotic.
Supporting Information
Figure S1 Location of 7 Hospitals participating in the invasive
pneumococcal disease surveillance network of Bangladesh. 1.
Dhaka Medical College Hospital (N=11); 2. Dhaka Shishu
Hospital (N=141); 3. Shishu Shasthya Foundation (N=27); 4.
Shalimullah Medical College Hospital (N=10); 5. Kumudini
Medical College Hospital (N=50); 6. Chittagong Ma O Shishu
Hospital (N=10); 7.Chittagong Medical College Hospital (N=8).
(N=Number of strains obtained from network hospitals and used
for the primer validation.)
Found at: doi:10.1371/journal.pone.0003576.s001 (0.79 MB TIF)
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